Drugs / SNC109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06616727 | Dec 2023 → Dec 2024 overdue | glioblastoma | Shanghai Simnova Biotechnology Co.,Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNC-109 | “SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells” NCT06616727 ↗1“Drug: SNC109” NCT06616727 ↗ |
| Modality | Cell therapy | “SNC-109 CAR-T Cells” NCT06616727 ↗ |